Arcutis Director Sells $121,000 Amid ZORYVE Revenue Surge
A biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
Monitoring expenses reveals patterns like recurring charges or impulsive buys. Look for spikes, then adjust categories to optimize your plan.
17,195 articlesA biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
Berkshire Hathaway's Greg Abel recently bought Macy's stock, sparking questions about value and strategy. This in-dep...
Are there real opportunities hiding in plain sight? This guide explains why the market may be getting these stocks wr...
A Live Oak Bancshares director sold 8,400 shares for about $336,000. Learn what this kind of insider action can signa...
SpaceX captures headlines with bold tech and presumed multi-bagger upside. Still, the stock question isn’t simple. Th...
An executive stock sale can signal many things. This article breaks down the numbers, the reporting rules, and practi...
The IDX framework sits at the center of a pivotal industry debate as market power concentrates and data becomes a str...
NVIDIA has slipped about 17% from its May high, leaving investors debating whether the AI powerhouse is finally a bar...
A multistate settlement with Block, the company behind Cash App, brings money back to consumers including Minnesota. ...
Tech stocks can swing fast. When shares intel have plummeted, investors must separate noise from fundamentals. This g...
Analysts sometimes cut targets right before a big earnings release. This piece explains why that timing can mislead i...
Investors are weighing two AI powerhouses: Amazon and Alphabet. This guide breaks down which may offer the stronger p...